Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex Enbrel

Executive Summary

Changes to the current vial stopper and potentially to the product delivery configuration are being evaluated following approximately 50 reports "from patients who are experiencing difficulties in penetrating the vial stopper with the needle on the supplied syringe, resulting in bent and otherwise damaged needles," firm says in recent "Dear Doctor" letter. The letter includes a revised video of instructions for preparing and administering Enbrel. The company said the letter was sent to prepare health care professionals in anticipation of Enbrel approval for the new indication of treatment of early stage rheumatoid arthritis (1"The Pink Sheet" April 24, p. 10). The user fee deadline for the sBLA is May 15

You may also be interested in...



Immunex Plans Enbrel Early RA Consumer Ad Campaign For Summer Launch

Immunex will roll out a new series of direct-to-consumer print ads to support Enbrel for early rheumatoid arthritis following FDA approval of the new indication, expected this summer.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel